Carbapenem Hydrolysing Oxacillinase in Acinetobacter baumannii
DOI:
https://doi.org/10.63939/0h70qx09Keywords:
Acinetobacter baumannii, CHDLs, carbapenem-hydrolyzing, β-lactamasesAbstract
The global rise in carbapenem resistance in Acinetobacter baumannii is alarming, as it severely restricts available therapeutic options. Among the resistance mechanisms identified in this species, carbapenem-hydrolyzing class D β-lactamases (CHDLs) represent the most prevalent β-lactamases and are largely specific to A. baumannii. This review focuses on the different clusters of oxacillinases that have been reported in Acinetobacter baumannii worldwide
Downloads
References
1. Gordon NC, Wareham DW (2010). Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Internat. J. Antimicrob Agents., 35: 219-226.
2. Giamarellou H, Antoniadou A, Kanellakopoulou K (2008). Acinetobacter baumannii: a universal threat to public health? International Journal of Antimicrobial Agents., 32: 106–119.
3. Zarrilli R, Crispino M, Bagattini M, Barretta E, Di Popolo A, Triassi M, Villari P (2004). Molecular Epidemiology of Sequential Outbreaks of Acinetobacter baumannii in an Intensive Care Unit Shows the Emergence of Carbapenem Resistance. J. Clin. Microbiol.,42: 946–953.
4. Beceiro A, Pérez A, Ferna´ndez-Cuenca F, Martínez-Martínez L, Pascual A, Vila J, Rodríguez-Ban˜o J, Cisneros J M, Pacho´n J, Bou G, and the Spanish Group for Nosocomial Infection (GEIH)(2009). Genetic Variability among ampC Genes from Acinetobacter Genomic Species. Antimicrob. Agents Chemother., 53:1177–1184.
5. Hanane El Hafa (2025) Molecular epidemiology of carbapenemase-encoding genes in Acinetobacter baumannii isolates from Morocco: A systematic review (2019–2024). Gene Reports ., 40 , Page 102289
6. Jain R, Danziger ZH (2004). Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to Clinicians Infect Diseases., 38: 1449-1559.
7. Youn Sung J, KyeChul Kwon, MD, Jong Woo Park MD, Yeon Suk Kim MD, JiMyung Kim MD, Kyeong Seob Shin MD, Jong Wan Kim MD, Chi SeonKo MD, So Youn Shin MD, JeongHoon Song, MD, Sun Hoe Koo MD (2008). Dissemination of IMP-1 and OXA Type β-Lactamase in Carbapenem-resistant Acinetobacter baumannii. Korean J Lab Med. ,28:16-23.
8. Fernández-Cuenca F, Martínez-Martínez L, Conejo MC, Ayala JA, Perea EJ, Pascualla A (2003). Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother.,51: 565–574.
9. Naas T, Nordmann P (1999). OXA-type β-lactamases. CurrPharm Des., 5: 865–879.
10. Naas T, Nordmann P (2005). Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter spp. In Europe. J Clin Microbiol., 43:4885−4888.
11. Poirel L, Nordmann P (2006). Carbapenem resistance in Acinetobacter baumannii: mechanisms and Epidemiology. Clin.Microbiol. Infect., 12: 826–836.
12. Poirel L, Pitout JD, Nordmann P (2007). Carbapenemases: molecular diversity and clinical consequences. Future Microbiol.,2:501–512.
13. Poirel L, NaasT, Nordmann P (2010). Diversity, Epidemiology, and Genetics of Class D β-Lactamases. Antimicrob. Agents Chemother., 54: 24–38.
14. Scaife W, Young HK, Paton RH, Amyes SG (1995). Transferable imipenem-resistance in Acinetobacter species from a clinical source. J Antimicrob. Chemother., 36: 585–586.
15. Van Looveren H. Goossens and the ARPAC Steering Group (2004). Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect., 10: 684–704.
16. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA (2007). Global Challenge of Multidrug-Resistant Acinetobacter baumannii., 51: 3471–3484.
17. Queenan AM, Bush K (2007). Carbapenemases: the versatile β- lactamases. Clin. Microb Reviews., 20: 440-458.
18. Afzal-Shah M, Woodford N, Livermore DM (2001). Characterization of OXA-25, OXA-26, and OXA-27, Molecular Class D β-Lactamases Associated with Carbapenem Resistance in Clinical Isolates of Acinetobacter baumannii. Antimicrob., Agents Chemother., 45:583–588.
19. Touati M, Diene SM, Racherache A, Dekhil M, Djahoudi A, Rolain JM (2012). Emergence of blaOXA-23 and blaOXA-58 carbapenemase-encoding genes in multidrug-resistant Acinetobacter baumannii isolates from University Hospital of Annaba, Algeria. Int J Antimicrob Agents., 40(1):89-91.
20. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A (2009). Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries.,5:335-341.
21. Da Silva GJ, Quinteira S, Bertolo E, Sousa JC, Gallego L, Duarte A, Peixe L, on behalf of the Portuguese Resistance Study Group (2004). Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumanniiclone in the Iberian Peninsula. J. Antimicrob. Chemother.,54:255–258.
22. Bou G, Oliver A, Beltran JS (2000). OXA-24, a Novel Class D β-Lactamase with Carbapenemase Activity in an Acinetobacter baumannii Clinical Strain. . Antimicrob. Agents Chemother., 44:1556–1561.
23. Héritier C, Poirel L, Aubert D, Nordmann P (2003). Genetic and Functional Analysis of the Chromosome-Encoded Carbapenem-Hydrolyzing Oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob. Agents Chemother., 47:268-273.
24. Quinteira S, Grosso F, Ramos h, Peixe (2007). Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. Antimicrob. Agents Chemother.,51:3465–3466.
25. Tian GB, Adams-Haduch JM, Bogdanovich T, Pasculle AW, Quinn JP, Wang HN, Doi Y (2011). Identification of diverse OXA-40 group carbapenemases, including a novel variant, OXA-160, from Acinetobacter baumannii in Pennsylvania. Antimicrob. Agents Chemother. ,55(1):429-32.
26. Wang, H., P. Guo, H. Sun, H. Wang, Q. Yang, M. Chen, Y. Xu, and Y. Zhu (2007). Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob. Agents Chemother.,51:4022–4028.
27. Mugnier P D, Bindayna KM, Poirel L, Nordmann P (2009). Diversity of plasmid-mediated carbapenem-hydrolysing oxacillinases among carbapenem-resistant Acinetobacter baumannii isolates from Kingdom of Bahrain. J. Antimicrob. Chemother.,63:1071–1073.
28. Lu P L, Doumith M, Livermore DM, Chen TP, Woodford N (2009). Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J. Antimicrob. Chemother.,63:641–647.
29. Lee K, Kim MN, Cho TY, Cho SE, Lee S, Whang DH, Yong D, Chong Y, Woodford N, Livermore DM, and the KONSAR Group (2009). Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea. Int. J. Antimicrob., Agents 33:520–524.
30. Werneck JS, Picão RC, Carvalhaes CG, Cardoso JP, Gales AC (2011). OXA-72-producing Acinetobacter baumannii in Brazil: a case report.J AntimicrobChemother. , 66(2):452-4.
31. Goic-Barisic I, Towner KJ, Kovacic A, Sisko-Kraljevic K, Tonkic M, Novak A, Punda-Polic V (2011). Outbreak in Croatia caused by a new carbapenem-resistant clone of Acinetobacter baumannii producing OXA-72 carbapenemase. J Hosp Infect., 77(4):368-9.
32. Montealegre MC, Maya JJ, Correa A, Espinal P, Mojica MF, Ruiz SJ, Rosso F, Vila J, Quinn JP, Villegas MV (2012). First identification of OXA-72 carbapenemase from Acinetobacter pittii in Colombia. Antimicrob Agents Chemother.,56(7):3996-8.
33. Marque S, Poirel L, Heritier C, Brisse S, Blasco MD, Filip R, Coman G, Naas T, Nordmann P (2005). Regional Occurrence of Plasmid-Mediated Carbapenem-Hydrolyzing Oxacillinase OXA-58 in Acinetobacter spp. in Europe. J. Clini. Microbio., 43: 4885–4888.
34. Marti S, Sánchez-Céspedes J, Blasco MD, Espinal P, Ruiz M, Alba V, Vila J (2008). Characterization of the carbapenem-hydrolyzing oxacillinase OXA-58 in an Acinetobacter phenon 6/ct13TU clinical isolate. Diagnostic Microbiology Infect Disease., 61: 468–470.
35. Poirel L, Marque S, Héritier C, Segonds C, Chabanon G, Nordmann P (2005). OXA-58, a Novel Class D β-Lactamase Involved in Resistance to Carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother., 49: 202–208.
36. Sevillano E, Fernández E, Bustamante Z, Zabalaga S, Rosales I, Umaran A, Gallego L (2012). Emergence and clonal dissemination of carbapenem-hydrolysing OXA-58-producing Acinetobacter baumannii isolates in Bolivia. J Med Microbiol., 61:80-4.
37. Figueiredo DQ, Santos KR, Pereira EM, Schuenck RP, Mendonça-Souza CR, Teixeira LM, Mondino SS (2011).First report of the bla (OXA-58) gene in a clinical isolate of Acinetobacter baumannii in Rio de Janeiro, Brazil.MemInst Oswaldo Cruz., 106(3):368-70.
38. Poirel L, Mansour W, Bouallegue O, Nordmann P (2008). Carbapenem-Resistant Acinetobacter baumannii Isolates from Tunisia Producing the OXA-58-Like Carbapenem-Hydrolyzing Oxacillinase OXA-97. Antimicrobe Agents Chemotherapy., 52: 1613–1617.
39. Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H (2009). OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother., 53(12):5035-8.
40. Gionco B, Pelayo JS, Venancio EJ, Cayô R, Gales AC, Carrara-Marroni FE (2012). Detection of OXA-231, a new variant of bla OXA-143, in Acinetobacter baumannii from Brazil: a case report. J Antimicrobe Chemother., 67(10):2531-2.
41. Héritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P (2005). Characterization of the Naturally Occurring Oxacillinase of Acinetobacter baumannii. Antimicrob Agents Chemotherapy., 49: 4174-4179.
42. Ikonomodis A, Pournaras S, Markogiannakis A, Maniatis AN, Manolis EN, Tsakris A (2007). Low genetic diversity of the intrinsic OXA-51-like class D carbapenemases among Acinetobacter baumannii clinical isolates in Greece. Epidemiol. Infect., 135: 877–881.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
